Catalyst Biosciences, Inc. (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions in the fields of hemostasis. Catalyst’s most advanced program, an improved next-generation coagulation Factor VIIa variant, has successfully completed a phase 1 clinical trial in severe hemophilia A and B patients. Catalyst has two other next-generation coagulation factors in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, visit the company’s website at www.catalystbiosciences.com